You are here
INTEGRAL MOLECULAR INC
https://www.integralmolecular.com/
UEI: DY9KSWE8EJB8
# of Employees: 100
HUBZone Owned: No
Socially and Economically Disadvantaged: No
Woman Owned: No
Award Charts
Award Listing
-
High-throughput Discovery of Antibodies against Understudied Membrane Proteins
Amount: $295,924.00ABSTRACT Of the 20,000 genes in the human genome, approximately 4,000 are considered “druggable” by pharmaceuticals. However, less than 10% of these druggable proteins are actually targeted by FDA ...
SBIRPhase I2023Department of Health and Human Services National Institutes of Health -
Reagents for Immunologic Analysis of Under-represented Mammalian Models
Amount: $600,000.00Integral Molecular proposes to generate a large panel of pan-reactive monoclonal antibodies (mAbs) against immune cell markers to be used instudies of immune function and responses in nine underrepres ...
SBIRPhase I2023Department of Health and Human Services National Institutes of Health -
ADJUVANT TARGET DISCOVERY FOR VACCINES AND FOR AUTOIMMUNE AND ALLERGIC DISEASES.
Amount: $600,000.00Using their unique Membrane Proteome Array (MPA)technology, the contractor will screen a comprehensive library of human cell surface proteins to identify novel immunomodulatory targets that regulate d ...
SBIRPhase I2022Department of Health and Human Services National Institutes of Health -
Identifying Regulators of Cellular Aging that can Prevent Alzheimer's Disease
Amount: $447,566.00ABSTRACT Aging is the leading risk factor for Alzheimer’s Disease (AD) and many other chronic diseases, with more than 6.5 million cases of AD in the US. Regulating or slowing cellular aging, partic ...
SBIRPhase I2022Department of Health and Human Services National Institutes of Health -
Development of Claudin MAbs for Treating Solid Tumors
Amount: $1,309,145.00ABSTRACT Solid tumors lead to 580,000 deaths annually in the US, and safe and effective therapeutics for many late- stage solid tumors are lacking. Ovarian cancer alone kills 14,000 people each year, ...
SBIRPhase II2022Department of Health and Human Services National Institutes of Health -
Development of Nav1.7 Monoclonal Antibodies for Treating Pain
Amount: $474,833.00ABSTRACT Chronic pain is a significant medical problem, affecting over 50 million Americans and representing the largest cause of disability and disease burden globally. Current pain relief treatments ...
SBIRPhase I2021Department of Health and Human Services National Institutes of Health -
Development of Kv1.3 Monoclonal Antibodies Targeting TEM Cells for Treating Autoimmune Disorders
Amount: $1,809,645.00ABSTRACT T cell-mediated autoimmune and chronic inflammatory diseases affect 23 million Americans, corresponding to ~$100B/year in direct healthcare costs. Pharmaceutical advances have enabled the dev ...
SBIRPhase II2020Department of Health and Human Services National Institutes of Health -
Next Generation Specificity Screening for Biotherapeutics using an Extracellular Proteome Array
Amount: $1,640,679.00ABSTRACT Detailed specificity analysis is critical for drugs, as even minimal off-target binding can cause serious adverse events. As a result, specificity profiling has become an FDA requirement for ...
SBIRPhase II2020Department of Health and Human Services National Institutes of Health -
Identifying Agonist MAbs against GPCRs
Amount: $355,360.00ABSTRACT Monoclonal antibodiesMAbsthat target G protein coupled receptorsGPCRsare difficult to isolateand agonist MAbsthat activate GPCRsare even more difficult to discoverIsolating functional MAbs ag ...
SBIRPhase I2018Department of Health and Human Services National Institutes of Health -
Identifying New Immunomodulatory Targets for Alzheimers and Other Neurodegenerative Diseases
Amount: $414,721.00ABSTRACT Alzheimerandapos s diseaseADand other neurodegenerative diseases are a major cause of death and disability for older Americanswith a US prevalence of more thanmillionAs AD currently cannot be ...
SBIRPhase I2018Department of Health and Human Services National Institutes of Health